These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19217709)

  • 21. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
    Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
    Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
    Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
    Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
    Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer.
    Choi JH; Ahn KS; Kim J; Hong YS
    Exp Mol Med; 2000 Mar; 32(1):23-8. PubMed ID: 10762058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway.
    Vanajothi R; Srinivasan P
    J Recept Signal Transduct Res; 2016; 36(3):292-302. PubMed ID: 26585176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.
    Cimas FJ; Callejas-Valera JL; Pascual-Serra R; García-Cano J; Garcia-Gil E; De la Cruz-Morcillo MA; Ortega-Muelas M; Serrano-Oviedo L; Gutkind JS; Sánchez-Prieto R
    Oncotarget; 2015 Dec; 6(42):44095-107. PubMed ID: 26689986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
    Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
    Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy induction by low-dose cisplatin: the role of p53 in autophagy.
    Cho KH; Park JH; Kwon KB; Lee YR; So HS; Lee KK; Lee SY; Moon SR; Yang SH
    Oncol Rep; 2014 Jan; 31(1):248-54. PubMed ID: 24173208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
    Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
    Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
    Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
    Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
    Ling YH; Zou Y; Perez-Soler R
    Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
    Dohadwala M; Yang SC; Luo J; Sharma S; Batra RK; Huang M; Lin Y; Goodglick L; Krysan K; Fishbein MC; Hong L; Lai C; Cameron RB; Gemmill RM; Drabkin HA; Dubinett SM
    Cancer Res; 2006 May; 66(10):5338-45. PubMed ID: 16707460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.